The Food and Drug Administration is considering whether to require opioid manufacturers to make available in-home disposal systems to address the risks posed by unused opioids in American homes. Companies selling opioid analgesics are currently required to make available prepaid mail-back envelopes to outpatient pharmacies and other dispensers, but the agency is exploring additional options.
FDA Commissioner Marty Makary, M.D., M.P.H., stated that having unused opioids laying around at home can be a significant risk to those struggling with opioids and can be a gateway for opioid-naïve family members. He emphasized the need to develop creative ways to address opioid misuse and abuse.
Current Disposal Methods and Research
At present, the FDA recommends dropping off unused opioids at a drug take-back location or mailing them back using a pre-paid envelope provided by a pharmacy. Alternatively, the FDA recommends flushing unused opioids down the toilet, something the agency only recommends for certain high-risk medications. A 2017 study in the Science of Total Environment concluded that flushing unused opioids presents a “negligible eco-toxicological risk.”
The FDA’s Request for Information seeks input from industry, health care providers, and advocates on appropriate criteria for in-home disposal kits. This aligns with the SUPPORT for Patients and Communities Reauthorization Act of 2025, which mandates the FDA to issue guidance to facilitate in-home safe disposal, as well as President Trump’s Great American Recovery initiative.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110828984/FDA-To-Address-Unused-Opioids-In-American-Homes